Compliance with Bisphosphonate Therapy and Fracture Risk
Author Information
Author(s): Jonathan Adachi, Niall Lynch, Hans Middelhoven, Manjit Hunjan, Warren Cowell
Primary Institution: McMaster University
Hypothesis
Is there a relationship between compliance and persistence with bisphosphonate therapy and the risk of fractures in postmenopausal women?
Conclusion
Suboptimal compliance and persistence with bisphosphonates does not provide the best protection against PMO fracture risk.
Supporting Evidence
- Women with an MPR of ≥80% had a 21% lower risk of fracture compared to those with an MPR of <80%.
- Persistence with treatment for 24 months was associated with a 29% lower risk of fracture.
- A nested case control study found that 12 months of persistence was associated with a 26% reduced risk of fracture.
Takeaway
If women take their osteoporosis medicine regularly, they are less likely to break a bone. But many don't take it as they should.
Methodology
A structured literature search was performed to identify studies evaluating the relationship between compliance and persistence with bisphosphonates and fracture risk.
Potential Biases
Potential biases due to reliance on prescription data and incomplete recording of fractures.
Limitations
The studies were based on observational data, which may overestimate compliance and persistence levels.
Participant Demographics
Women aged over 45 years with osteoporosis or osteopenia.
Statistical Information
P-Value
p < 0.001
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website